Cabazitaxel
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2010
- First approval year
- 2010
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Cabazitaxel
- Molecular weight
- 835.94
- Structure (SMILES)
- CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C
- cabazitaxel accord
- Cabazitaxel accord
- jevtana
- Jevtana
- jevtana kit
- Jevtana kit
- 1 hydroxy 7 beta 10 beta dimethoxy 9 oxo 5 beta 20 epoxytax 11 ene 2 alpha 4 13 alpha triyl 4 acetate 2 benzoate 13 2r 3s 3 tert butoxy carbonyl amino 2 hydroxy 3 phenylpropanoate
- 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)
- 100 mg cabazitaxel
- 200 mg cabazitaxel
- 50 mg cabazitaxel
- cabazitaxel
- Cabazitaxel
- CABAZITAXEL
- cabazitaxel (XRP6258)
- Cabazitaxel (XRP6258)
- CABAZITAXEL (XRP6258)
- cabazitaxel (XRP6258) (RPR116258)
- CABAZITAXEL [EMA EPAR]
- cabazitaxel [INN]
- CABAZITAXEL [MART.]
- CABAZITAXEL [MI]
- CABAZITAXEL [ORANGE BOOK]
- CABAZITAXEL [USAN]
- CABAZITAXEL [VANDF]
- Cabazitaxel [WHO-DD]
- Cabazitaxel 60 mg Solution for Injection
- cabazitaxel acetonate
- Cabazitaxel acetonate
- CABAZITAXEL ACETONATE [JAN]
- cabazitaxel acetonate jan
And 26 more, listed on the interactive page.
- CAS registry numbers
- 183133-96-2
- ChEMBL ID
- CHEMBL1201748
- InChIKey
- BMQGVNUXMIRLCK-OAGWZNDDSA-N
- PubChem compound IDs
- 9854073
- RxNorm IDs (RxCUI)
- 996051
- FDA ingredient codes (UNII)
- 51F690397J
- L01CD
- L01CD04
Sources for recorded values
- Applicant
- SANOFI AVENTIS US
- Approval date
- 17 Jun 2010
- Application number
- NDA201023
- Status
- Authorised
- Status date
- 17 Mar 2011
- Authorisation date
- 17 Mar 2011
- Approved indications
- Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
- Product number
- EMEA/H/C/002018
- Authorisation holder
- Sanofi Winthrop Industrie
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 1
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Prostatic Neoplasms
European medicines record
- Patents
- 10
- Designations
- 2
- Earliest recorded loss of exclusivity
- 27 Apr 2031
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- cabazitaxel
- Type
- Synthetic organic
- Drug name stem
- -taxel
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tubulin beta class I
- Gene symbol
- TUBB
- Protein identifier
- P07437
- Primary target
- Yes
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P04350
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P07437
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P0DPH7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68363
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68366
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68371
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13509
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13885
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q3ZCM7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q6PEY2
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q71U36
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BQE3
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BUF5
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BVA1
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9H4B7
Open Targets mechanisms
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8
- Protein identifier
- P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Glioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000326
- Subject identifier
- D005910
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Liposarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003085
- Subject identifier
- D008080
- Condition
- Testicular Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005088
- Subject identifier
- D013736
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Carcinoma, Transitional Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000601
- Subject identifier
- D002295
- Condition
- Adrenal Cortex Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000796
- Subject identifier
- D000306
- Condition
- Penile Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001094
- Subject identifier
- D010412
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Brain Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001657
- Subject identifier
- D001932
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004986
- Subject identifier
- D001749
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
And 1 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000326
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003085
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005088
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006859
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008528
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000566
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000601
- Condition identifier
- EFO_1000796
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001094
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001657
- Condition identifier
- MONDO_0003890
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005040
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005060
- Highest recorded phase
- 2
And 27 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- anaemia
- Reports
- 52
- Reporting signal score
- 18.1669
- Event
- bone lesion
- Reports
- 15
- Reporting signal score
- 41.7931
- Event
- bone pain
- Reports
- 21
- Reporting signal score
- 16.3543
- Event
- cystitis haemorrhagic
- Reports
- 10
- Reporting signal score
- 22.4397
- Event
- decreased appetite
- Reports
- 47
- Reporting signal score
- 24.6194
- Event
- diarrhoea
- Reports
- 93
- Reporting signal score
- 18.2283
- Event
- disease progression
- Reports
- 46
- Reporting signal score
- 39.7149
- Event
- drug hypersensitivity
- Reports
- 1
- Reporting signal score
- 18.6404
- Event
- dysuria
- Reports
- 16
- Reporting signal score
- 15.9732
- Event
- embolism
- Reports
- 11
- Reporting signal score
- 18.6537
- Event
- extravasation
- Reports
- 11
- Reporting signal score
- 20.2707
- Event
- febrile neutropenia
- Reports
- 99
- Reporting signal score
- 174.562
- Event
- general physical health deterioration
- Reports
- 26
- Reporting signal score
- 15.8367
- Event
- haematuria
- Reports
- 41
- Reporting signal score
- 60.8706
- Event
- headache
- Reports
- 10
- Reporting signal score
- 17.7111
- Event
- hormone-refractory prostate cancer
- Reports
- 12
- Reporting signal score
- 49.0412
- Event
- hydronephrosis
- Reports
- 26
- Reporting signal score
- 65.584
- Event
- interstitial lung disease
- Reports
- 29
- Reporting signal score
- 27.4844
- Event
- lacrimation increased
- Reports
- 13
- Reporting signal score
- 15.929
- Event
- leukopenia
- Reports
- 25
- Reporting signal score
- 16.731
- Event
- malignant neoplasm progression
- Reports
- 47
- Reporting signal score
- 56.6608
- Event
- metastases to bone
- Reports
- 27
- Reporting signal score
- 57.6685
- Event
- metastases to lung
- Reports
- 10
- Reporting signal score
- 15.9523
- Event
- metastases to lymph nodes
- Reports
- 20
- Reporting signal score
- 52.9012
- Event
- metastases to soft tissue
- Reports
- 7
- Reporting signal score
- 33.0889
And 17 more, listed on the interactive page.
- NCT00417079
- NCT01335204
- NCT01576029
- NCT01952223
- NCT01981668
- NCT02703623
- NCT02844582
- NCT06353386
- NCT00925743
- NCT01941550
- NCT01001221
- NCT01087021
- NCT01140607
- NCT01447225
- NCT01527929
- NCT01755390
- NCT01083615
- NCT01254279
- NCT01308567
- NCT01308580
- NCT01324583
- NCT01420250
- NCT01511536
- NCT01518283
- NCT01531205
And 65 more, listed on the interactive page.
- Dose
- 20 mg/m2
- Route
- Intravenous
- How often
- Every three weeks
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 3
- Polar surface area
- 202.45
- Calculated partition coefficient (ALogP)
- 4.57
- Calculated partition coefficient (XLogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 10
- Heavy atoms
- 60
- Molecular formula
- C45H57NO14
- Monoisotopic mass
- 835.37790549
- Natural product
- Yes
- Recorded assays
- 387
- Active assays
- 166
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (113)
- A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
- A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
- A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
- A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer
- A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
- A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
- A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
- A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
- A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
- A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
- A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Approved for (7)
- Cancer
- Metastatic prostate carcinoma
- Neoplasm
- Prostate adenocarcinoma
- Prostate cancer
- Prostate carcinoma
- Prostate neoplasm
In development for (21)
- Adrenal cortex carcinoma Phase 2
- Brain cancer Phase 1
- Breast cancer Phase 2
- Central nervous system cancer Phase 1
- Colorectal cancer Phase 2
- Dedifferentiated liposarcoma Phase 2
- Gastric cancer Phase 2
- Glioblastoma Phase 2
- Head and neck cancer Phase 2
- Head and neck squamous cell carcinoma Phase 2
- Infiltrating bladder urothelial carcinoma Phase 2
- Non-small cell lung carcinoma Phase 2
- Nongerminomatous germ cell tumor Phase 2
- Ovarian cancer Phase 2
- Penile neoplasm Phase 2
- Small cell lung carcinoma Phase 2
- Testicular cancer Phase 2
- Testicular germ cell tumor Phase 2
- Transitional cell carcinoma Phase 2
- Urinary bladder carcinoma Phase 2
Targets (15)
- TUBA1A Tubulin inhibitor
- TUBA1B Tubulin inhibitor
- TUBA1C Tubulin inhibitor
- TUBA3C Tubulin inhibitor
- TUBA3E Tubulin inhibitor
- TUBA4A Tubulin inhibitor
- TUBB Tubulin inhibitor
- TUBB1 Tubulin inhibitor
- TUBB2A Tubulin inhibitor
- TUBB2B Tubulin inhibitor
- TUBB3 Tubulin inhibitor
- TUBB4A Tubulin inhibitor
- TUBB4B Tubulin inhibitor
- TUBB6 Tubulin inhibitor
- TUBB8 Tubulin inhibitor